share_log

Biodexa Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Cavalry Fund I LP(9.9%),Cavalry Fund I Management LLC(9.9%), etc.

SEC announcement ·  Dec 28, 2023 13:00
Summary by Futu AI
On December 21, 2023, Biodexa Pharmaceuticals PLC, a company listed on The Nasdaq Capital Market under the symbol BDRX, was the subject of a Schedule 13G filing with the Securities and Exchange Commission. The filing was made by a group of related investment entities and an individual, collectively referred to as the Reporting Persons. These include Cavalry Fund I LP, Cavalry Fund I Management LLC, Cavalry Investment Fund LP, Cavalry Fund GP, LLC, and Thomas Walsh, a U.S. citizen. The filing indicates that these entities and Mr. Walsh collectively hold a significant number of ordinary shares and American Depositary Shares (ADSs) of Biodexa Pharmaceuticals, which represent a 9.9% and 8.1% ownership stake respectively. The shares include those issuable upon the exercise of warrants, which are subject to a 9.99% beneficial ownership blocker, preventing the Reporting Persons from exceeding this ownership threshold. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Biodexa Pharmaceuticals.
On December 21, 2023, Biodexa Pharmaceuticals PLC, a company listed on The Nasdaq Capital Market under the symbol BDRX, was the subject of a Schedule 13G filing with the Securities and Exchange Commission. The filing was made by a group of related investment entities and an individual, collectively referred to as the Reporting Persons. These include Cavalry Fund I LP, Cavalry Fund I Management LLC, Cavalry Investment Fund LP, Cavalry Fund GP, LLC, and Thomas Walsh, a U.S. citizen. The filing indicates that these entities and Mr. Walsh collectively hold a significant number of ordinary shares and American Depositary Shares (ADSs) of Biodexa Pharmaceuticals, which represent a 9.9% and 8.1% ownership stake respectively. The shares include those issuable upon the exercise of warrants, which are subject to a 9.99% beneficial ownership blocker, preventing the Reporting Persons from exceeding this ownership threshold. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Biodexa Pharmaceuticals.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.